V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330008917 | 330005709 | 1.79 | 65 | Curative (C) | 2017-12-24 | 2018-01-05 | Cytarabine intrathecal | N | N | 330023091 | CYCLO + ETOPOSIDE + VINCRISTINE |
| 330008918 | 330005709 | null | 93.9 | Palliative (P) | 2013-12-23 | 2014-01-05 | Eribulin | N | N | 330023091 | CLOFARABINE + CYTARABINE |
| 330008919 | 330005710 | 1.38 | 76 | null | 2016-07-17 | 2016-07-17 | CYCLOPHOSPHAMIDE | N | N | 330023102 | EDP |
| 330008920 | 330005711 | 1.81 | 54.55 | Palliative (P) | 2017-12-25 | 2018-01-01 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | N | 330023102 | CISPLATIN + GEMCITABINE |
| 330008921 | 330005711 | 1.78 | null | Palliative (P) | 2017-05-09 | 2017-07-17 | Dox + HD Mtx (post PAM) | N | N | 330023102 | FCR |
| 330008922 | 330005712 | 1.81 | 79.6 | Adjuvant (A) | 2014-06-26 | 2014-06-26 | BLINATUMOMAB | 2 | N | 330023125 | CYTARABINE |
| 330008923 | 330009117 | 1.7 | null | Adjuvant (A) | null | 2016-10-21 | Mitotane 2g | N | null | 330023138 | CYTARABINE |
| 330008924 | 330010951 | null | 75.2 | Palliative (P) | 2017-12-18 | 2017-12-18 | ALL UKALL 2011 HD MtxA (Protocol M) | N | null | 330023141 | ALDESLEUKIN |
| 330008925 | 330005713 | null | 56.5 | Palliative (P) | null | 2014-05-27 | VIDE | null | null | 330023156 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330008926 | 330009118 | null | null | Curative (C) | 2016-05-04 | 2016-05-22 | Ifosfamide 3g/m2 5 day | N | N | 330023159 | ETOPOSIDE + IFOSFAMIDE + MTX |
| 330008927 | 330005714 | 1.82 | null | Curative (C) | 2013-08-30 | 2013-08-31 | Carboplatin + Doxorubicin | 2 | N | 330023161 | DOCETAXEL + NINTEDANIB |
| 330008928 | 330005716 | 1.73 | 18.7 | Palliative (P) | 2014-11-16 | 2015-03-01 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 330023161 | OFATUMUMAB |
| 330008929 | 330005717 | 1.76 | 64.1 | Palliative (P) | 2015-08-10 | 2015-09-06 | MABCUTE TRIAL | null | N | 330023226 | BENDAMUSTINE |
| 330008930 | 330005718 | -1 | null | null | null | 2017-12-02 | MACE | null | null | 330023226 | CARBOPLATIN + CETUXIMAB + FU |
| 330008931 | 330005719 | 1.57 | 74.3 | Curative (C) | 2015-10-24 | 2015-10-25 | Cytarabine low (10to20mg/m2) IV/SC | 02 | null | 330023240 | IPO |
| 330008932 | 330005722 | 1.55 | null | Not known (9) | 2017-10-29 | 2017-11-27 | RUXOLITINIB | 02 | N | 330023242 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330008933 | 330005722 | 1.58 | 47.8 | Curative (C) | 2017-05-06 | 2017-11-12 | MELPHALAN | N | N | 330023242 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330008934 | 330005723 | null | 77 | Curative (C) | null | 2015-04-23 | Alemtuz+Fludara+Melphalan RIC MUD | null | null | 330023248 | UKALL 2011 |
| 330008935 | 330010954 | 1.65 | 45.1 | Palliative (P) | 2018-04-16 | 2018-04-16 | STS Rhabdo RMS 2005 Vin Cyclo | N | N | 330023268 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330008936 | 330011963 | 1.82 | null | Palliative (P) | 2017-08-30 | 2017-09-26 | IBRUTINIB | 02 | N | 330023268 | MERCAPTOPURINE |
| 330008937 | 330011964 | 1.77 | 81.3 | Adjuvant (A) | 2018-04-23 | 2018-05-07 | STS Rhabdomyosarcoma RMS 2005 IVA | N | null | 330023279 | DOXORUBICIN + METHOTREXATE |
| 330008938 | 330005728 | 1.71 | 51.4 | Palliative (P) | 2013-12-21 | 2013-12-22 | AML17 TRIAL | 1 | N | 330023279 | FCR |
| 330008939 | 330005728 | null | 60.6 | Palliative (P) | 2013-03-19 | 2013-03-25 | Bortezomib +/- Dexamethasone | N | N | 330023279 | CYTARABINE IT + METHOTREXATE |
| 330008940 | 330005728 | 1.16 | 52.1 | null | 2015-12-24 | 2015-12-26 | CISPLATIN + METHOTREXATE + VINCRISTINE | null | null | 330023279 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330008941 | 330005729 | 1.57 | 60.8 | Curative (C) | 2017-12-19 | 2017-12-26 | Bevacizumab | 2 | N | 330023321 | PILOT TRIAL |
| 330008942 | 330005730 | null | 77.95 | Curative (C) | 2015-06-18 | 2015-06-27 | Cisplatin + Fluorouracil + RT 5day | N | N | 330023327 | CAP |
| 330008943 | 330005731 | 1.85 | 68.1 | Palliative (P) | 2018-04-13 | 2018-04-17 | LIPOSOMAL DAUNORUBICIN | N | N | 330023330 | THALIDOMIDE |
| 330008944 | 330005732 | 1.72 | 62.8 | Palliative (P) | 2019-01-31 | 2019-02-13 | Lenalidomide Cycle 26 onwards (PAS) | Y | N | 330023336 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330008945 | 330005734 | 1.72 | 98.9 | Curative (C) | 2014-10-06 | 2014-10-06 | CAPECITABINE + VINORELBINE | 2 | N | 330023338 | FIGARO TRIAL |
| 330008947 | 330005738 | null | 61.5 | Curative (C) | 2016-05-12 | 2016-05-12 | VINCRISTINE | N | N | 330023346 | BEP |
| 330008948 | 330005739 | 1.65 | 77.1 | Curative (C) | 2014-02-11 | 2014-02-12 | LENALIDOMIDE + dexamethasone | N | N | 330023346 | DOXORUBICIN + IFOSFAMIDE |
| 330008949 | 330005740 | 1.74 | 89.15 | Disease modification (D) | 2015-09-30 | 2015-09-30 | BORTEZOMIB + RITUXIMAB | Y | null | 330023349 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330008950 | 330005741 | 1.64 | 43.1 | Curative (C) | 2013-03-04 | 2013-03-06 | PCV | 02 | N | 330023353 | DOXORUBICIN + HD MTX |
| 330008951 | 330005741 | 1.83 | 45.6 | Curative (C) | 2018-06-03 | 2018-06-07 | Capecitabine + Cisplatin | N | N | 330023353 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330008952 | 330005748 | 1.68 | 75.7 | Adjuvant (A) | 2016-09-09 | 2016-10-03 | CISPLATIN + VINORELBINE | N | N | 330023358 | HYDROXYCARBAMIDE |
| 330008953 | 330005750 | 1.82 | 75.2 | null | 2017-03-25 | 2017-04-01 | CYCLOPHOSPHAMIDE + ETOPOSIDE + VINCRISTINE | N | N | 330023377 | UKALL 2011 |
| 330008954 | 330005751 | null | 80.5 | Curative (C) | 2013-06-08 | 2013-06-15 | CAPECITABINE + IRINOTECAN | N | N | 330023377 | DHAP |
| 330008955 | 330005752 | 1.83 | 69 | Neo-adjuvant (N) | null | 2016-02-14 | Ifosfamide | 02 | null | 330023403 | CYTARABINE |
| 330008956 | 330005753 | 1.7 | 13.2 | Adjuvant (A) | 2013-05-18 | 2013-06-16 | Doxorubicin + Methotrexate | null | N | 330023405 | MAP + MIFAMURTIDE |
| 330008957 | 330009139 | 1.75 | 96 | null | null | 2017-03-01 | AML 19 TRIAL | null | null | 330023408 | VINCRISTINE |
| 330008958 | 330005755 | 1.79 | 8.8 | Palliative (P) | 2014-05-05 | 2014-05-05 | ADE 10+3+5 | 02 | N | 330023409 | BEP |
| 330008959 | 330005756 | 1.83 | 23.6 | Palliative (P) | 2014-05-14 | 2014-06-10 | BLEOMYCIN + CISPLATIN + VINCRISTINE | N | N | 330023409 | VIDE |
| 330008960 | 330005756 | null | 38.3 | null | null | 2013-09-19 | BORTEZOMIB + RITUXIMAB | null | N | 330023409 | RUXOLITINIB |
| 330008961 | 330005756 | null | 58 | Disease modification (D) | 2013-12-30 | 2014-01-04 | UKALL14- Cons Cycle 3 | N | null | 330023409 | LENALIDOMIDE |
| 330008962 | 330005757 | 0 | 65.8 | Palliative (P) | 2017-01-16 | 2017-01-16 | Trastuzumab Subcutaneous | Y | null | 330023430 | DOXORUBICIN + HD MTX |
| 330008963 | 330005757 | null | 51.9 | null | null | 2017-02-26 | AML18 PILOT TRIAL | null | N | 330023430 | AML19 TRIAL |
| 330008964 | 330010961 | 1.8 | 81.3 | null | 2018-04-07 | 2018-04-15 | Topotecan (intravenous) | Y | N | 330023440 | ALDESLEUKIN |
| 330008965 | 330005758 | 1.68 | 53.3 | Palliative (P) | 2014-09-28 | 2014-10-02 | CYTARABINE | Y | N | 330023454 | AML17 TRIAL |
| 330008966 | 330005758 | 0 | 38.3 | Curative (C) | 2015-08-03 | 2015-08-19 | ALL UKALL2011 Maintenance B1 | N | N | 330023454 | INTERFERON |
| 330008967 | 330005758 | 1.23 | 71.3 | Curative (C) | 2018-08-10 | 2018-08-19 | IMATINIB | N | N | 330023454 | CHLORAMBUCIL + RITUXIMAB |